(Q39680200)

English

Vorinostat and sorafenib increase CD95 activation in gastrointestinal tumor cells through a Ca(2+)-de novo ceramide-PP2A-reactive oxygen species-dependent signaling pathway

scientific article published on 14 July 2010

In more languages
default for all languages
No label defined

No description defined

Statements

Vorinostat and sorafenib increase CD95 activation in gastrointestinal tumor cells through a Ca(2+)-de novo ceramide-PP2A-reactive oxygen species-dependent signaling pathway (English)
Margaret A Park
Clint Mitchell
Jeremy Allegood
Roland Reinehr
Andrew Larner
Paul B Fisher
Christina Voelkel-Johnson
Besim Ogretmen
Steven Grant

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit